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S U M M A R Y
Background: Acinetobacter baumannii has been reported increasingly as a signiﬁcant causative organism
of various nosocomial infections, including hospital-acquired pneumonia (HAP). The aim of this study
was to investigate the clinical characteristics of HAP induced by carbapenem-resistant A. baumannii
(CRAB) in elderly patients and the in vitro antimicrobial effects of cefoperazone/sulbactam combination
therapy.
Methods: Seventy-one elderly patients in the geriatric ward of the General Hospital of the People’s
Liberation Army (PLAGH) with CRAB-induced HAP were analyzed retrospectively. The checkerboard
method was used to determine the in vitro drug sensitivity of 60 CRAB strains to antimicrobial
combinations (cefoperazone/sulbactam with meropenem, minocycline, or levoﬂoxacin). The occurrence
of carbapenemase genes was detected by PCR.
Results: CRAB-induced HAP occurred mostly in patients with underlying diseases. Prior to onset, most
patients had received antimicrobial therapies including broad-spectrum b-lactams, invasive mechanical
ventilation, and catheterization. The 30-day survival rate was 95.1% in patients using cefoperazone/
sulbactam, with or without combination with antimicrobial drugs, and 73.3% in patients not using
cefoperazone/sulbactam (p < 0.05). When cefoperazone/sulbactam was used in combination with
minocycline, levoﬂoxacin, and meropenem, minimum inhibitory concentrations MIC50 and MIC90 were
reduced for each drug. The genes OXA-23 and OXA-51 were ampliﬁed in 96.7% of the strains, but the
genes OXA-24, OXA-58, SIM, VIM, and IMP were not ampliﬁed.
Conclusions: CRAB-induced HAP occurred mostly in patients with anemia or decreased levels of serum
albumin, but with elevated levels of C-reactive protein and creatinine. Cefoperazone/sulbactam in
combination with minocycline, meropenem, and levoﬂoxacin had a synergistic and additive in vitro
bacteriostatic action on CRAB.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
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Acinetobacter baumannii, a non-fermenting Gram-negative
aerobic coccobacillus, has emerged as one of the most troublesome
pathogens in the healthcare setting, both globally and locally.1 Its
remarkable ability to develop or acquire multiple antibiotic
resistance and its propensity to survive for prolonged periods* Corresponding author. Tel.: +86 10 88286628; fax: +86 10 88286628.
E-mail address: fangxq301@126.com (X. Fang).
1 These authors contributed equally to this work.
http://dx.doi.org/10.1016/j.ijid.2014.01.017
1201-9712  2014 The Authors. Published by Elsevier Ltd on behalf of International Sounder a wide range of environmental conditions, make it a
frequent cause of hospital outbreaks and an endemic healthcare-
associated pathogen for pneumonia.2 The elderly population is
particularly susceptible to such outbreaks given their decreased
immunity, aspiration, and malnutrition.3
Carbapenem is a preferred drug of choice for the treatment of
multidrug-resistant A. baumannii. However, the overuse of
imipenem has resulted in the emergence of carbapenem-resistant
A. baumannii (CRAB) around the world.4 In 2010, data from the
Ministry of Health National Antimicrobial Resistance Investigation
Net (Mohnarin) indicated that the clinical isolation rate of A.
baumannii exceeded that of Pseudomonas aeruginosa in 14 teachingciety for Infectious Diseases. Open access under CC BY-NC-ND license.
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prevalent nosocomial infection.3 Consequently interest in
polymyxins, sulbactam, and tigecycline, the only antibiotics with
in vitro activity against this organism,5–8 has increased.
In the current retrospective analysis, the characteristics of
CRAB-induced hospital-acquired pneumonia (HAP) in elderly
patients were investigated, and the therapeutic effects of various
cefoperazone/sulbactam combination therapies were analyzed.
2. Methods
2.1. Setting, patients, and data collection
The current study was approved by the Institutional Review
Board of the General Hospital of the People’s Liberation Army
(PLAGH), Beijing, China. Seventy-one elderly patients in the
geriatric ward of PLAGH (hospitalized due to chronic obstructive
pulmonary disease (COPD), cerebrovascular accident, lung cancer,
or congestive heart failure) who had non-life-threatening nosoco-
mial infections (absence of any of the following: systolic blood
pressure < 90 mmHg or 40 mmHg below the patient’s normal
pressure; respiratory rate >30/min; oliguria/anuria; room air PaO2
<60 mmHg; PaO2/FiO2 <250; multiple lobes involved; or involve-
ment of the central nervous system) with multi-resistant A.
baumannii from January 2008 to August 2011 were analyzed
retrospectively. Inclusion criteria were age 60 years (mean age
was 86  8 years, range 60–101 years), with diagnostic criteria of
HAP,9 triplicate positive A. baumannii sputum cultures (under the
conditions of pure culture or dominant growth), and resistance to
imipenem and meropenem of the isolated A. baumannii strains. The
time span from hospitalization to the pneumonia was relatively wide,
but was in line with HAP standards.9
Clinical data were collected, including (1) general health
conditions before onset (sex, age, underlying diseases, etc.); (2)
diagnostic and treatment measures before onset (treatment with
invasive mechanical ventilation, catheterization, and antacids); (3)
use of antimicrobial drugs within 14 days before onset; (4) clinical
manifestations at onset (main symptoms and the results of routine
blood tests, biochemical tests, and chest X-ray); (5) results of drug
sensitivity testing; (6) antimicrobial therapies after onset; and (7)
survival 30 days post-onset. For patients admitted to an intensive
care unit, the Acute Physiology and Chronic Health Evaluation II
(APACHE II) score and Clinical Pulmonary Infection Score (CPIS)
were assessed within 24 h.10,11 Anemia (hemoglobin <120 g/l),
low serum albumin (<35 g/l), elevated creatinine (>110 mmol/l),
elevated blood urea nitrogen (>7.1 mmol/l), APACHE II score, and
CPIS of both the survivors and those who died were used to analyze
risk factors for death.
2.2. Pathogen identiﬁcation and antimicrobial susceptibility testing
Sputum samples were cultured for organism identiﬁcation
according to a conventional method and the antimicrobial
susceptibility of the isolates was determined with the Kirby–
Bauer method. Antibiotics tested were amikacin, aztreonam,
cefoperazone/sulbactam, ciproﬂoxacin, cefepime, gentamicin,
levoﬂoxacin, minocycline, polymyxin B, cefoperazone, piperacillin,
trimethoprim/sulfamethoxazole, ceftazidime, and piperacillin/
tazobactam. Results were interpreted using clinical breakpoints
as deﬁned in the 2010 Clinical and Laboratory Standards Institute
(CLSI) guidelines.12 PCR ampliﬁcations were done to detect the
occurrence of three groups of OXA-carbapenemase-encoding
genes (blaOXA-23-like, blaOXA-24-like, blaOXA-51-like, and
blaOXA-58-like) and three groups of the metallo-b-lactamase-
encoding genes (blaIMP, blaVIM, and blaSIM), as described
previously.13,142.3. Combined drug sensitivity testing
Sixty CRAB strains were isolated from the 71 patients. Escherichia
coli ATCC 25922, Escherichia coli ATCC 35218, and Pseudomonas
aeruginosa ATCC 27853 were used as control strains. Cefoperazone/
sulbactam was used in combination with minocycline, meropenem,
or levoﬂoxacin. The drug sensitivity tests were assessed using
checkerboard and broth microdilution methods.15 Brieﬂy, colonies
picked from fresh overnight cultures on Mueller–Hinton (MH) agar
plates were enriched in MH broth and adjusted to match the 0.5
McFarland turbidity and diluted to 1.5  105 CFU/ml. Cefoperazone/
sulbactam, minocycline, meropenem, and levoﬂoxacin were serially
diluted with MH broth (128–0.063 mg/ml). Subsequently, drugs of
different concentrations were designed with the checkerboard
method and added to a 96-well plate in pair-wise combinations,
50 ml of each. Finally 100 ml of 1.5  105 CFU/ml bacterial solution
was added to each well and cultured overnight at 37 8C.
The minimum inhibitory concentrations (MIC) of single use
(MICsingle A and MICsingle B) or combination use (MICcombined A or
MICcombined B) drugs were recorded, and the fractional inhibitory
concentration (FIC) index was calculated using the following
formula: FIC = (MICcombined use of drug A/MICsingle use of drug A) +
(MICcombined use of drug B/MICsingle use of drug B). A FIC 0.5
demonstrated synergy, 0.5 < FIC  1 demonstrated additivity, 1
< FIC  2 demonstrated an indifferent interaction, and FIC >2
demonstrated antagonism.15
2.4. Statistical analysis
Count data were assessed using the Chi-square test,16
measurement data were analyzed using the Student’s t-test,17
and the data in non-normal distribution were analyzed using the
rank-sum test.18 A p-value of <0.05 was considered signiﬁcant.
3. Results
3.1. Clinical data and microbiological outcomes
Most of the patients (88.7%) had anemia (hemoglobin <120 g/l)
and 71.6% had decreased levels of serum albumin (<35 g/l) at
onset. Interestingly, 23.9% of the patients had no fever and 45.1%
did not have elevated white blood cell levels (WBC; >10  109/l).
On the other hand, 83.1% had elevated levels of neutrophils
(neutrophils >70%) and 87.9% had elevated levels of C-reactive
protein (CRP >8 mg/dl). Most of the patients (91.5%) had bronchial
pneumonia (affected patches throughout both lungs, as revealed
on chest X-ray) and only 8.5% had lobar pneumonia (Table 1).
In addition, 47.9% of the patients had a cerebrovascular disease,
36.6% had type II diabetes mellitus, and 28.2% had COPD. Within 14
days prior to onset, 64.8% of the patients were put on cephalosporins,
60.6% on carbapenems, 47.9% on quinolones, and 35.2% on broad-
spectrum penicillins. Also, 63.4% of the patients underwent invasive
mechanical ventilation, 70.4% had two or more catheters inserted
(inclusive of urinary catheter, nasogastric feeding tube, vena cava
catheter, and tracheal intubation), and 81.0% of the patients were
given antacids including proton pump inhibitors and H2 receptor
blockers. A signiﬁcant difference was observed in the APACHE II
score between the survivors and those who died (p = 0.001);
however, no signiﬁcant difference in other factors was observed
between the two outcome groups (p > 0.05) (Table 2).
3.2. Antimicrobial susceptibility and pathogen determination
CRAB susceptibility to all antibiotics tested, except for polymyxin
B, was <5%. CRAB susceptibility to polymyxin B was 64.6%. Interes-
tingly, even though CRAB susceptibility to cefoperazone/sulbactam
Table 1
Demographic characteristics, underlying diseases, catheter use, antibiotic use, and
clinical manifestations in 71 patients
Item Total Number of
positive cases
Positive
rate (%)
Gender, male 71 64 90.1
Age, years, average  SD (range) 86  8 (60–101)
Underlying diseases
Cerebrovascular disease 71 34 47.9
Diabetes 71 26 36.6
COPD 71 20 28.2
Lung cancer 71 11 15.5
Chronic renal failure 71 8 11.3
Congestive heart failure 71 6 8.5
Antibiotic use
Cephalosporins 71 46 64.8
Carbapenems 71 43 60.6
Quinolones 71 34 47.9
Broad-spectrum penicillins 71 25 35.2
Catheter use
Stomach tube 71 59 83.1
Vena cava 71 57 80.3
Urinary catheter 71 52 73.2
Invasive mechanical ventilation 71 45 63.4
Clinical manifestations
Fever 71 54 76.1
WBC count >10  109/la 71 39 54.9
Neutrophils >70% 71 59 83.1
Platelets <100  109/l 71 12 16.9
Anemiab 71 63 88.7
Elevated CRPc 66 58 87.9
Elevated creatinined 69 21 30.4
Serum albumin <35 g/l 67 48 71.6
AST increasee 69 14 20.3
ALT increasee 69 11 15.9
Chest X-ray
Patchy exudation 71 65 91.5
Consolidation 71 6 8.5
SD, standard deviation; COPD, chronic obstructive pulmonary disease; WBC, white
blood cell; CRP, C-reactive protein; AST, aspartate aminotransferase; ALT, alanine
aminotransferase.
a Normal range 3.5–10  109/l.
b Hemoglobin <137 g/l in males; hemoglobin <116 g/l in female.
c CRP >0.8 mg/dl.
d Creatinine >110 mmol/l.
e AST >40 U/l; ALT >40 U/l.
Table 4
Distribution of the bacteriostatic index of drug combinations (FIC index) (%)
Drug combination FIC 0.5 0.5 < FIC  1 1 < FIC  2 FIC >2
CFS + MER 28.3 53.4 18.3 0
CFS + MIN 11.7 45 35 8.3
CFS + LEV 6.7 40 53.3 0
FIC, fractional inhibitory concentration; CFS, cefoperazone/sulbactam; MER,
meropenem; MIN, minocycline; LEV, levoﬂoxacin.
Table 3
Minimum inhibitory concentration (MIC) of CRAB (mg/ml; n = 60) in the cases of
cefoperazone/sulbactam (CFS) combined with minocycline (MIN), levoﬂoxacin
(LEV), and meropenem (MER)
Combination of antibiotic drugs Single use Combined
use
MIC50 MIC90 MIC50 MIC90
CFS + MER MER 64 128 16 64
CFS 128 256 32 64
CFS + MIN CFS 128 256 64 64
MIN 8 16 2 16
CFS + LEV CFS 128 256 64 64
LEV 2 4 1 4
CRAB, carbapenem-resistant Acinetobacter baumannii.
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observed in 40.6% of cases. OXA-23 and OXA-51 genes were
ampliﬁed from 58 of 60 strains of CRAB (96.7%). However, the drug
resistance genes including OXA-24, OXA-58, SIM, VIM, and IMP were
not ampliﬁed.
3.3. The prognosis differed signiﬁcantly in the different treatment
groups
Because the patients in the current study were elderly patients,
polymyxins were not used to avoid renal toxicity. Due to the fact that
57.6% of the patients received treatment with cefoperazone/sulbactam
or antimicrobial combinations containing cefoperazone/sulbactam, allTable 2
Analysis of risk factors for death in CRAB-mediated hospital-acquired pneumonia
Variable Survived Died t-Value p-Value
Hemoglobin 102.12  15.76 96.10  32.26 1.331 0.183
Albumin, g/l 33.07  3.82 33.27  4.94 0.145 0.8854
Creatinine, mmol/l 89.57  50.22 118.29  74.71 1.50 0.133
Urea nitrogen, mmol/l 14.68  8.80 19.46  14.27 1.38 0.167
APACHE II score 18.07  6.5 25.78  4.35 3.265 0.001a
CPIS 7.42  1.99 7.89  1.45 0.665 0.5088
CRAB, carbapenem-resistant Acinetobacter baumannii; APACHE II, Acute Physiology
and Chronic Health Evaluation II; CPIS, Clinical Pulmonary Infection Score.
a Statistically signiﬁcant.of them were divided into two groups for the statistical analysis: the
cefoperazone/sulbactam group and the non-cefoperazone/sulbactam
group. The 30-day survival rate in the cefoperazone/sulbactam group
was 96.4% and in the non-cefoperazone/sulbactam group was 73.3%
(p < 0.05).
3.4. Combined drug sensitivity test results
When cefoperazone/sulbactam was used in combination with
either minocycline or levoﬂoxacin, the MIC50 and MIC90 of
cefoperazone/sulbactam were 1/2 and 1/4 of the MIC of the single
drug, respectively. However, when it was combined with
meropenem, both the MIC50 and MIC 90 of cefoperazone/sulbactam
were 1/4 of the MIC of the single drug (Table 3).
The FIC index of drug combinations showed synergy or
additivity when cefoperazone/sulbactam was used in combination
with meropenem, minocycline, or levoﬂoxacin: 81.7%, 56.7%, and
46.7%, respectively (Table 4). Moreover, when these drugs were
used in combination, the MIC50 and MIC90 were reduced for each
drug.
4. Discussion
During the last two decades, A. baumannii has evolved to
demonstrate one of the most efﬁcient antibiotic resistance
patterns, making it a nosocomial pathogen of great signiﬁcance
in the healthcare setting. A majority of patients in the current study
presented with elevated neutrophils and CRP levels in conjunction
with bronchial pneumonia. Acid suppressants, proton pump
inhibitors, and histamine receptor antagonists are associated with
a high risk of community- and hospital-acquired pneumonia,19–22
the mechanism of which is not clear. Eighty-one percent of the
patients in the current study were given antacids including proton
pump inhibitors and H2 receptor blockers, which might explain the
high incidence of CRAB-mediated HAP.
In our study, the rate of resistance of CRAB isolates to
ciproﬂoxacin, cefepime, cefoperazone, and piperacillin/tazobac-
tam reached 100%. The isolates also showed high resistance to
aztreonam, levoﬂoxacin, piperacillin, trimethoprim/sulfamethox-
azole, and ceftazidime, which is consistent with the ﬁndings of a
previous report.23 The rate of resistance to aminoglycosides like
amikacin and gentamicin, as well as polymyxin B, exceeded 95%
and 35%, respectively, consistent with previous studies.24,25
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direct bacteriostatic effect on A. baumannii. The speciﬁc in vitro
activity of sulbactam against Acinetobacter spp, which is related to
its afﬁnity for penicillin-binding proteins, is well known;26–30 it
has recently been utilized in clinical practice. Sulbactam has an
inhibitory effect on carbapenem-hydrolyzing OXA-type b-lacta-
mase and a synergistic effect on other b-lactam antibiotics.31 In
this study, the 30-day survival rate was signiﬁcantly higher in
patients who received cefoperazone/sulbactam or drug combina-
tions containing cefoperazone/sulbactam, compared to patients
who did not receive cefoperazone/sulbactam, indicating that
cefoperazone/sulbactam has a certain inhibitory effect on CRAB-
induced HAP in elderly patients.
The antimicrobial susceptibility testing of cefoperazone/sulbac-
tam used in combination with meropenem, minocycline, or
levoﬂoxacin showed synergistic and additive effects, indicating that
antimicrobial combinations mainly with cefoperazone/sulbactam
have a certain combined effect on CRAB. In addition, about half of the
A. baumannii isolates from this group of patients were intermediate
to cefoperazone/sulbactam. Cumulatively, the aforementioned
reasons explain the higher 30-day survival rate in patients who
received cefoperazone/sulbactam, either singly or in combination,
compared to patients who did not receive cefoperazone/sulbactam.
A previous study has reported that sulbactam has a certain
inhibitory effect on OXA-23 enzyme-producing CRAB,32 which
partly explains our observation that cefoperazone/sulbactam and
antimicrobial drug combinations containing cefoperazone/sulbac-
tam had synergistic and additive bacteriostatic action in vitro on
CRAB strains.
In summary, our study showed that CRAB-induced HAP mostly
occurred in patients with underlying diseases and that cefoper-
azone/sulbactam has a certain inhibitory effect on CRAB-induced
HAP in this group. The results of combined drug sensitivity testing
showed cefoperazone/sulbactam in combination with minocy-
cline, meropenem, or levoﬂoxacin to have synergistic and additive
bacteriostatic action in vitro. One limitation of the current study
was that no risk factor analysis was performed; hence, whether the
lower mortality observed in the group of patients treated with
cefoperazone/sulbactam alone or in combination versus those who
did not receive cefoperazone/sulbactam was due to treatment or
other factors, e.g., the severity of the pneumonia or co-morbidities,
is not absolutely certain. However, our results indicate that there is
potential beneﬁt, pending further investigation, of the use of
cefoperazone/sulbactam in these patients. These study results
should provide references for the treatment of CRAB-induced HAP
in elderly patients.
Conﬂict of interest: The authors declare that they do not have any
conﬂict of interest to report.
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